LIDDS Investor Relations Material
LIDDS AB is a pharmaceutical company, which develops and sells pharmaceutical products for cancer and other diseases in Sweden. It produces various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO for the treatment of metastatic colorectal cancer; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. The company has collaboration with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. LIDDS AB is based in Uppsala, Sweden.
Marvel-ous Reporting: Marvel’s Comic Inspired Reports
Shareholder reports are often considered tedious and dry. However, in the late 1980s and early 1990s, Marvel Comics revolutionized this perception by transforming its financial reports into captivating comic books.
8 Dec 2023
The Payments Value Chain: A Complex Ecosystem
The payments industry is a complex and dynamic field involving multiple key players. These include customers, merchants, issuers, acquirers, card networks, and various other entities together forming the payments value chain.
8 Dec 2023
NIBE: Creating Millionaires and a Greener Future
NIBE, just like IKEA, was founded in a rural part of Sweden called Småland. The company offers a wide range of pumps, wood stoves, and solar panels.
6 Dec 2023